Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. 1988

T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

Acute hemodynamic and humoral effects of synthesized alpha human atrial natriuretic polypeptide (alpha-hANP, 0.025 microgram/kg/min for 40 min) on 6 patients with severe congestive heart failure were assessed. Plasma alpha-hANP concentration was high in patients and increased further (from 463 +/- 360 to 1,282 +/- 670 pg/ml, mean +/- SD, p less than 0.01) following alpha-hANP infusion, but plasma norepinephrine (1,030 +/- 865 to 971 +/- 785 pg/ml) was not changed. Increases in urine output (1.0 +/- 0.8 to 2.6 +/- 2.3 ml/min) and Na+ excretion rate (87 +/- 89 to 257 +/- 211 mEq/min/m2) were statistically insignificant. A significant reduction was induced in mean aortic pressure (99 +/- 25 to 96 +/- 26 mmHg, p less than 0.05), mean right atrial pressure (11 +/- 9 to 7 +/- 8 mmHg, p less than 0.01), mean pulmonary arterial pressure (39 +/- 13 to 33 +/- 12 mmHg, p less than 0.05) and mean pulmonary capillary wedge pressure (27 +/- 8 to 20 +/- 7 mmHg, p less than 0.01). Heart rate, cardiac index, systemic vascular resistance and pulmonary vascular resistance were not altered. In conclusion, alpha-hANP induced decreases in left ventricular filling pressure and rightside heart pressure which were attributed to venodilatation rather than natriuresis in patients with congestive heart failure. Preserved cardiac output with decreased preload suggested that alpha-hANP improved cardiac function.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011652 Pulmonary Circulation The circulation of the BLOOD through the LUNGS. Pulmonary Blood Flow,Respiratory Circulation,Circulation, Pulmonary,Circulation, Respiratory,Blood Flow, Pulmonary,Flow, Pulmonary Blood,Pulmonary Blood Flows
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
January 1987, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
December 1999, The Journal of cardiovascular surgery,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
August 1987, Clinical pharmacology and therapeutics,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
January 1986, Chinese medical journal,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
July 1988, Giornale italiano di cardiologia,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
April 1993, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
March 1985, European journal of pharmacology,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
June 1987, Sheng li xue bao : [Acta physiologica Sinica],
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
January 1990, The American journal of cardiology,
T Serizawa, and Y Hirata, and O Kohmoto, and M Iizuka, and H Matsuoka, and H Sato, and T Takahashi, and T Mochizuki, and M Ishii, and T Sugimoto
January 1986, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!